drugset / Trial / NCT01100307

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

NCT01100307

Phase 3 Completed 243 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study to assess the efficacy of pegaptanib sodium 0.3 mg comparing sham injection and to confirm safety of pegaptanib sodium 0.3 mg in subjects with diabetic macular edema.

Timeline

Start
2010-05
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer 0.3 mg Intravitreal